Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence.

Weber AT, Shah ND, Sauk J, Limketkai BN.

Curr Treat Options Gastroenterol. 2019 Nov 8. doi: 10.1007/s11938-019-00248-z. [Epub ahead of print] Review.

PMID:
31705371
2.

Classifying Enteral Nutrition: Tailored for Clinical Practice.

Limketkai BN, Shah ND, Sheikh GN, Allen K.

Curr Gastroenterol Rep. 2019 Jul 31;21(9):47. doi: 10.1007/s11894-019-0708-3. Review.

PMID:
31368086
3.

The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2019 Feb 25;7(1). pii: E27. doi: 10.3390/diseases7010027. Review.

4.

INTESTINAL DYSMOTILITY MIMICKING OBSTRUCTION IN PATIENTS WITH PRIOR BOWEL RESECTION SURGERY.

Choe MY, Shah ND, Regalia K, Limketkai BN.

Gastroenterol Nurs. 2019 Jan/Feb;42(1):95-100. doi: 10.1097/SGA.0000000000000425. No abstract available.

PMID:
30688712
5.

Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.

Cholankeril R, Patel V, Perumpail BJ, Yoo ER, Iqbal U, Sallam S, Shah ND, Kwong W, Kim D, Ahmed A.

Diseases. 2018 Oct 3;6(4). pii: E93. doi: 10.3390/diseases6040093. Review.

6.

When to Initiate Weight Loss Medications in the NAFLD Population.

Yoo ER, Sallam S, Perumpail BJ, Iqbal U, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 30;6(4). pii: E91. doi: 10.3390/diseases6040091. Review.

7.

Judicious Use of Lipid Lowering Agents in the Management of NAFLD.

Iqbal U, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 24;6(4). pii: E87. doi: 10.3390/diseases6040087. Review.

8.

The Role of Vitamin E in the Treatment of NAFLD.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 24;6(4). pii: E86. doi: 10.3390/diseases6040086. Review.

9.

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD.

Dibba P, Li AA, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 19;6(3). pii: E83. doi: 10.3390/diseases6030083. Review.

10.

Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD.

Perumpail BJ, Li AA, Iqbal U, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 10;6(3). pii: E80. doi: 10.3390/diseases6030080. Review.

11.

Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease.

Limketkai BN, Sepulveda R, Hing T, Shah ND, Choe M, Limsui D, Shah S.

Scand J Gastroenterol. 2018 Feb;53(2):147-151. doi: 10.1080/00365521.2017.1409364. Epub 2017 Dec 7.

PMID:
29216767
12.

Short Bowel Syndrome and Intestinal Failure in Crohn's Disease.

Limketkai BN, Parian AM, Shah ND, Colombel JF.

Inflamm Bowel Dis. 2016 May;22(5):1209-18. doi: 10.1097/MIB.0000000000000698. Review.

PMID:
26818425
13.

Oral Diets and Nutrition Support for Inflammatory Bowel Disease: What Is the Evidence?

Shah ND, Parian AM, Mullin GE, Limketkai BN.

Nutr Clin Pract. 2015 Aug;30(4):462-73. doi: 10.1177/0884533615591059. Epub 2015 Jun 17. Review.

PMID:
26084506
14.

Nutraceutical Supplements for Inflammatory Bowel Disease.

Parian AM, Limketkai BN, Shah ND, Mullin GE.

Nutr Clin Pract. 2015 Aug;30(4):551-8. doi: 10.1177/0884533615586598. Epub 2015 May 29. Review. No abstract available.

PMID:
26024677
15.

Asymmetric peptide dendrimers are effective linkers for antibody-mediated delivery of diverse payloads to b cells in vitro and in vivo.

Shah ND, Parekh HS, Steptoe RJ.

Pharm Res. 2014 Nov;31(11):3150-60. doi: 10.1007/s11095-014-1408-1. Epub 2014 May 22.

PMID:
24848340
16.

Pediatric patients' orthodontic treatment need, quality of life, and smiling patterns -- an analysis of patient, parent, and provider responses.

Shah ND, Arruda A, Inglehart MR.

J Public Health Dent. 2011 Winter;71(1):62-70. doi: 10.1111/j.1752-7325.2010.00203.x.

PMID:
21070243
17.

Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival.

Kim AW, Faber LP, Warren WH, Shah ND, Basu S, Liptay MJ.

J Thorac Cardiovasc Surg. 2010 Mar;139(3):606-11. doi: 10.1016/j.jtcvs.2009.05.044. Epub 2009 Aug 25.

18.

Cytologic imprints of giant atypical bronchopulmonary carcinoid tumor of the lung with extensive oncocytic component.

McIntire M, Shah ND, Kim AW, Gattuso P, Liptay MJ.

Diagn Cytopathol. 2008 Dec;36(12):887-90. doi: 10.1002/dc.20946.

PMID:
18855906

Supplemental Content

Loading ...
Support Center